J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Moltke, L.
Right arrow Articles by Shader, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Moltke, L.
Right arrow Articles by Shader, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

LL von Moltke, DJ Greenblatt, JM Grassi, BW Granda, SX Duan, SM Fogelman, JP Daily, JS Harmatz, and RI Shader

Four protease inhibitor antiviral agents (ritonavir, indinavir, nelfinavir, saquinavir) were evaluated as in vitro inhibitors of the activity of six human cytochromes using an in vitro model based on human liver microsomes. Ritonavir was a highly potent inhibitor of P450-3A activity (triazolam hydroxylation), having inhibitory potency slightly less than ketoconazole. Indinavir was also a potent 3A inhibitor, while nelfinavir and saquinavir were less potent. Ritonavir had high inhibition potency against cytochrome P450-2C9 (tolbutamide hydroxylation), -2C19 (S-mephenytoin hydroxylation), and -2D6 (dextromethorphan O-demethylation and desipramine hydroxylation), while the other protease inhibitors had one or more orders of magnitude lower inhibitory activity against these reactions. None of the protease inhibitors had important inhibitory potency against P450-1A2 (phenacetin O-deethylation) or -2E1 (chlorzoxazone hydroxylation). Thus, among available protease inhibitors, ritonavir carries the highest risk of incurring drug interactions due to inhibition of cytochrome P450 activity.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
N. Valin, N. De Castro, V. Garrait, A. Bergeron, C. Bouche, and J. M. Molina
Iatrogenic Cushing's Syndrome in HIV-Infected Patients Receiving Ritonavir and Inhaled Fluticasone: Description of 4 New Cases and Review of the Literature
J Int Assoc Physicians AIDS Care (Chic Ill), March 1, 2009; 8(2): 113 - 121.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. D Liedtke and R C. Rathbun
Warfarin-Antiretroviral Interactions
Ann. Pharmacother., February 1, 2009; 43(2): 322 - 328.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. S. Rhee and D. J. Greenblatt
Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly
J. Clin. Pharmacol., October 1, 2008; 48(10): 1212 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom
Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib
Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Liu, G. Foster, K. Gandelman, R. R. LaBadie, M. J. Allison, M. J. Gutierrez, and A. Sharma
Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects
Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3617 - 3626.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H.-Z. Bu, P. Zhao, P. Kang, W. F. Pool, E. Y. Wu, and B. V. Shetty
Evaluation of Capravirine as a CYP3A Probe Substrate: In Vitro and in Vivo Metabolism of Capravirine in Rats and Dogs
Drug Metab. Dispos., September 1, 2007; 35(9): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Stocker, C. Herzmann, A. Breske, G. Kruse, M. Berger, H. Schulbin, A. Hill, J. Steinmuller, M. Becker, K. Arasteh, et al.
Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration
J. Antimicrob. Chemother., March 1, 2007; 59(3): 560 - 564.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Farkas, L. E. Oleson, Y. Zhao, J. S. Harmatz, M. A. Zinny, M. H. Court, and D. J. Greenblatt
Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450-3A Activity: Comparison With Grapefruit Juice
J. Clin. Pharmacol., March 1, 2007; 47(3): 286 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J. Yang, M. Jamei, A. Heydari, K. R. Yeo, R. de la Torre, M. Farre, G. T. Tucker, and A. Rostami-Hodjegan
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA
J Psychopharmacol, November 1, 2006; 20(6): 842 - 849.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
H.-Z. Bu, P. Zhao, P. Kang, W. F. Pool, and E. Y. Wu
Identification of Enzymes Responsible for Primary and Sequential Oxygenation Reactions of Capravirine in Human Liver Microsomes
Drug Metab. Dispos., November 1, 2006; 34(11): 1798 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court
Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.
J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. S. Perloff, S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke
ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO
Drug Metab. Dispos., June 1, 2005; 33(6): 764 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Kato, R. Ieki, E. Saito, T. Ota, K. Yuasa, M. Iguchi, T. Okamura, and M. Shibuya
A Long-term Survival Case of Small Cell Lung Cancer in an HIV-infected Patient
Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 349 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Krishnaswamy, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and M. H. Court
EVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 1A6
Drug Metab. Dispos., August 1, 2004; 32(8): 862 - 869.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
B. Vitiello, M. A. Burnam, E. G. Bing, R. Beckman, and M. F. Shapiro
Use of Psychotropic Medications Among HIV-Infected Patients in the United States
Am J Psychiatry, March 1, 2003; 160(3): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Kumar, G. Y. Kwei, G. K. Poon, S. A. Iliff, Y. Wang, Q. Chen, R. B. Franklin, V. Didolkar, R. W. Wang, M. Yamazaki, et al.
Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5) with Ritonavir in Rats and Monkeys: Role of CYP3A and P-Glycoprotein
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1161 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. H. Tran, L. L. von Moltke, K. Venkatakrishnan, B. W. Granda, M. A. Gibbs, R. S. Obach, J. S. Harmatz, and D. J. Greenblatt
Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors
Drug Metab. Dispos., December 1, 2002; 30(12): 1441 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Raucy, L. Mueller, K. Duan, S. W. Allen, S. Strom, and J. M. Lasker
Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 475 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Hocqueloux, S. Gallien, C. Bornstain, and J.-M. Molina
Quadricyclic Antidepressant Overdosage in a Patient With AIDS Under Mega-Highly Active Antiretroviral Therapy
Arch Intern Med, October 8, 2001; 161(18): 2260 - 2261.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. L. von Moltke, D. J. Greenblatt, G. M. Giancarlo, B. W. Granda, J. S. Harmatz, and R. I. Shader
Escitalopram (S-Citalopram) and Its Metabolites in Vitro: Cytochromes Mediating Biotransformation, Inhibitory Effects, and Comparison to R-Citalopram
Drug Metab. Dispos., August 1, 2001; 29(8): 1102 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. M. Hesse, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
Ritonavir, Efavirenz, and Nelfinavir Inhibit CYP2B6 Activity in Vitro: Potential Drug Interactions with Bupropion
Drug Metab. Dispos., February 1, 2001; 29(2): 100 - 102.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
L. M. Hesse, K. Venkatakrishnan, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
CYP3A4 Is the Major CYP Isoform Mediating the in Vitro Hydroxylation and Demethylation of Flunitrazepam
Drug Metab. Dispos., February 1, 2001; 29(2): 133 - 140.
[Abstract] [Full Text]

Home page
 J Med MicrobiolHome page
C.A. HART, N.J. BEECHING, and B.I. DUERDEN
Infections in AIDS: Proceedings of the Sixth Liverpool Tropical School Bayer Symposium on Microbial Diseases held on 6 February 1999
J. Med. Microbiol., November 1, 2000; 49(11): 947 - 967.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Stormer, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
Metabolism of the Antidepressant Mirtazapine In Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4
Drug Metab. Dispos., October 1, 2000; 28(10): 1168 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. S. Warrington, R. I. Shader, L. L. von Moltke, and D. J. Greenblatt
In Vitro Biotransformation of Sildenafil (Viagra): Identification of Human Cytochromes and Potential Drug Interactions
Drug Metab. Dispos., April 1, 2000; 28(4): 392 - 397.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. S. Warrington, J. W. Poku, L. L. von Moltke, R. I. Shader, J. S. Harmatz, and D. J. Greenblatt
Effects of Age on In Vitro Midazolam Biotransformation in Male CD-1 Mouse Liver Microsomes
J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1024 - 1031.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
B. Ma, T. Prueksaritanont, and J. H. Lin
Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A
Drug Metab. Dispos., February 1, 2000; 28(2): 125 - 130.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology